Clinical Trial Update: JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events [Phase 3]

View source ↗

Summary

JUPITER evaluated rosuvastatin 20 mg vs placebo for prevention of cardiovascular events in individuals with elevated high-sensitivity C-reactive protein. The Ph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease

Drugs mentioned

• CRESTOR (Rosuvastatin)

Snippet

Sponsor: AstraZeneca | Conditions: Elevated High-sensitivity C-Reactive Protein (hsCRP) | Phase 3 | Status: TERMINATED | Results posted: 2014-03-24